-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recent popular reports from Yimaike ★AAV treats rare heart diseases, cell and gene therapy company completes US$106 million in Series C financing Yimai Meng broke the news ★AAV Daniel James Wilson led the research, one gene editing treatment successfully reduced cholesterol in animal models for three yearsMedMed broke the news on March 11, 2021/eMedClub News/--Recently (March 8, 2021), three gene therapies PBGM01, PBFT02 and PBKR03 created by Passage Bio were granted U.
S.
FDA fast track on the same day title.
Dr.
Bruce Goldsmith, President and CEO of Passage Bio, said: "At Passage Bio, we are working to address some of the world’s rarest and most devastating neurological diseases that affect infants and adults.
The FDA has decided to provide each of our lead genes.
The fast track designation by treatment candidates highlights the urgent need for new therapies for these diseases, and is an important step towards achieving our goal of providing patients with potential conversion therapies as soon as possible.
"Biopharmaceutical Innovation Technology Conference (BPIT) It will kick off in Shanghai from April 9th to 10th, 2021.
The four major conference venues will be exciting (click to view the focus topics).
Participants who successfully registered for the Shanghai 2021 BPIT conference will receive a limited edition of "CAR-T Cell Therapy Industry Research Report" 2021.
V3.
1 produced by Xingyao Research Institute under Medical Media.
S.
FDA fast track on the same day title.
Dr.
Bruce Goldsmith, President and CEO of Passage Bio, said: "At Passage Bio, we are working to address some of the world’s rarest and most devastating neurological diseases that affect infants and adults.
The FDA has decided to provide each of our lead genes.
The fast track designation by treatment candidates highlights the urgent need for new therapies for these diseases, and is an important step towards achieving our goal of providing patients with potential conversion therapies as soon as possible.
"Biopharmaceutical Innovation Technology Conference (BPIT) It will kick off in Shanghai from April 9th to 10th, 2021.
The four major conference venues will be exciting (click to view the focus topics).
Participants who successfully registered for the Shanghai 2021 BPIT conference will receive a limited edition of "CAR-T Cell Therapy Industry Research Report" 2021.
V3.
1 produced by Xingyao Research Institute under Medical Media.
